この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2026/4/241 分で読めます
Egis Pharmaceuticals Limited, et al.; Withdrawal of Approval of Three Abbreviated New Drug Applications
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is withdrawing approval of three abbreviated new drug applications (ANDAs) from the holders of those ANDAs. The basis for the withdrawal is that the ANDA holders have repeatedly failed to file required annual reports for those ANDAs.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →